[Changes in the activity of amyloid-degrading metallopeptidases leads to disruption of memory in rats]

Insights

Prenatal hypoxia and aging impair short-term memory by reducing metallopeptidases neprilysin (NEP) and endothelin-converting enzyme (ECE-1) in the brain cortex. Inhibiting these enzymes further disrupts memory, confirming their critical role in cognitive function.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Gerontology

Background:

  • Aging and prenatal hypoxia disrupt short-term memory in rats.
  • These conditions are associated with decreased expression of metallopeptidases neprilysin (NEP) and endothelin-converting enzyme (ECE-1) in the brain cortex.
  • NEP and ECE-1 are key enzymes involved in neuropeptide regulation and beta-amyloid peptide degradation.

Purpose of the Study:

  • To investigate the role of metallopeptidases NEP and ECE-1 in short-term memory.
  • To determine if inhibiting NEP and ECE-1 affects cognitive function.
  • To explore the link between metallopeptidase activity and memory deficits in aging and prenatal hypoxia models.

Main Methods:

  • Wistar rats (old and adult) subjected to prenatal hypoxia were assessed for short-term memory.
  • Brain cortex expression and activity of NEP and ECE-1 were measured.
  • Microinjections of phosphoramidon (NEP/ECE-1 inhibitor) and thiorphan (NEP inhibitor) into the sensorimotor cortex were performed.
  • Short-term memory was evaluated using a two-level radial maze test.

Main Results:

  • Prenatal hypoxia led to decreased NEP and ECE-1 expression and NEP activity in the sensorimotor cortex.
  • Microinjections of phosphoramidon and thiorphan into the sensorimotor cortex significantly disrupted short-term memory.
  • Memory impairment was observed at specific time points after enzyme inhibitor administration.

Conclusions:

  • Metallopeptidases NEP and ECE-1 are critically involved in maintaining short-term memory function.
  • Reduced expression and activity of these enzymes contribute to cognitive deficits observed in aging and after prenatal hypoxia.
  • Targeting NEP and ECE-1 may offer therapeutic strategies for memory disorders.

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Role of Neurotransmitters in Memory01:23

Role of Neurotransmitters in Memory

Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
 Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
Role of Amygdala in Memory01:16

Role of Amygdala in Memory

The amygdala is a small, almond-shaped structure responsible for processing and storing memories, particularly those linked to emotions like fear and stress. It plays an essential role in the brain's response to emotionally significant events and often enhances memory formation by triggering stress hormone release. The amygdala is vital for encoding and retrieving memories associated with fear or stress, a process that is adaptive by helping organisms avoid dangerous situations.
One of the...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...